NaF-18 PET for Bone Metastasis
This national coverage determination (NCD) was issued on February 26, 2010. It establishes specific clinical indications under which CMS will cover NaF-18 Positron Emission Tomography (NaF-18 PET). The NCD concluded that NaF-18 PET scans are reasonable and necessary under Section 1862(a)(1)(E) of the Social Security Act in the context of Coverage with Evidence Development (CED).
Prospectively under CED, NaF-18 PET imaging must lead to:
- A change in patient management to more appropriate palliative care; or
- A change in patient management to more appropriate curative care, or
- Improved quality of life; or
- Improved survival
The clinical research study also must adhere to certain standards of scientific integrity and relevance to the Medicare population.
On its website, CMS will maintain a list of all approved studies and facility locations. There are approximately 2200 facilities participating in the clinical research study for NaF-18 PET. A list of facility locations can be found here: http://www.cms.gov/MedicareApprovedFacilitie/NOPR/list.asp#TopOfPage
The following study has been approved by CMS: The National Oncologic PET Registry (NOPR)
Information on the clinical study may be found at: http://www.clinicaltrials.gov/ct2/show/NCT00868582?term=PET+Academy+of+Molecular+Imaging&rank=2
The protocol for FDG PET for Solid Tumors was amended to include a second clinical research study to include this NCD.
- Page last Modified: 03/31/2015 1:49 PM
- Help with File Formats and Plug-Ins